Streetbeat News

TCBP

TC Biopharm (Holdings) Plc

https://www.tcbiopharm.com

Industry

Biotechnology

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

TC BioPharm (NASDAQ: TCBP) announced that its American Depository Shares continue to trade on the Nasdaq Global Select Market without any interruptions. The company is a clinical-stage biotechnology firm focusing on gamma-delta T cell therapies for cancer.

Portfolio Pulse from

January 06, 2025 | 6:45 pm

TC BioPharm (NASDAQ: TCBP) is advancing negotiations with two acquisition candidates as part of its M&A strategy to expand its therapeutic platform.

Portfolio Pulse from

December 31, 2024 | 3:30 pm

TC BioPharm (NASDAQ: TCBP) has announced a 25% stock dividend, which was approved at the company's General Meeting. This move is part of the company's strategy as a clinical-stage biotechnology firm.

Portfolio Pulse from

December 30, 2024 | 3:45 pm

TC BioPharm (NASDAQ: TCBP) has completed the final dosing of 3 patients in its ACHIEVE Phase 2b clinical trial for TCB008, targeting AML and MDS/AML. No drug-related adverse events were reported, indicating a positive step in the trial's progress.

Portfolio Pulse from

December 20, 2024 | 1:45 pm

TC BioPharm (NASDAQ: TCBP) has announced a general meeting to approve a special dividend of 0.25 ADSs per 1 ADS held. This decision is pending shareholder approval.

Portfolio Pulse from

December 18, 2024 | 1:45 pm

TC BioPharm partners with CareDx to use AlloCell for pharmacokinetic monitoring in the ACHIEVE clinical trial, focusing on allogeneic gamma-delta T cell therapies for AML and MDS.

Portfolio Pulse from

December 11, 2024 | 12:15 pm

TC BioPharm (NASDAQ: TCBP) announced a positive update on their ACHIEVE UK clinical trial, with promising safety data allowing for higher doses of TCB008. The trial is progressing with four UK sites recruiting patients and two more expected by H1 2025.

Portfolio Pulse from

December 04, 2024 | 1:45 pm

TC BioPharm (NASDAQ: TCBP) has received $250,000 in non-dilutive funding from the G-Rex® Grant Program, a $20M initiative by ScaleReady, Wilson Wolf Manufacturing, and Bio-Techne Corporation to advance cell and gene-modified cell therapy development.

Portfolio Pulse from

November 12, 2024 | 2:45 pm

TC BioPharm has announced the signing of two non-binding letters of intent for acquisitions in cell therapy modalities outside its core TCB008. This move indicates a strategic expansion beyond its current focus.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 12:34 pm

LENZ Therapeutics shares rose 18% in pre-market trading following positive Phase 3 trial results in China. Other notable pre-market movers include Healthcare Triangle, Pixie Dust Technologies, and Jet.AI, with significant gains, while SMX and Upexi saw declines.

Portfolio Pulse from Avi Kapoor

October 28, 2024 | 10:32 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.